Twice-a-year shot to prevent HIV approved in U.S.

The approval of the world’s only twice-a-year shot to prevent HIV in the U.S. by Gilead Sciences has sparked hope for millions of people worldwide. The drug, lenacapavir, has shown promising results in two groundbreaking studies, nearly eliminating new infections in high-risk populations. This new option could be a game-changer in the fight against HIV, especially for those who struggle to adhere to daily preventive pills.

While a vaccine for HIV is still a priority, experts believe that lenacapavir could be the next best thing in preventing transmission. The six-month protection offered by this medication makes it the longest-lasting option available, which could appeal to individuals who prefer less frequent doctor visits or face stigma associated with daily pills.

However, challenges in the U.S. and globally, including cuts to public health agencies and foreign aid for HIV prevention, may hinder the widespread adoption of lenacapavir. The availability and affordability of the drug remain uncertain, raising concerns about access for those who need it most.

Gilead’s lenacapavir, known as Sunlenca for HIV treatment, will be marketed as Yeztugo for prevention. Administered as two injections under the skin of the abdomen, the drug slowly releases into the body over time. While the price has not been disclosed, it is important to note that lenacapavir only prevents HIV transmission and does not protect against other sexually transmitted diseases.

Efforts to end the HIV pandemic by 2030 have faced setbacks, with thousands of new infections reported each year in the U.S. and millions worldwide. Despite the proven efficacy of PrEP in reducing HIV transmissions, only a fraction of those who could benefit from it currently use it. Studies have shown that states with high PrEP usage have seen a decline in new infections, highlighting the importance of widespread access to preventive medications.

One of the trial participants, Ian Haddock, shared his positive experience with lenacapavir, stating that he no longer has to worry about taking a daily pill and can easily remember his biannual clinic visits. Haddock emphasized the importance of expanding access to effective prevention methods like lenacapavir for individuals at risk of HIV.

In conclusion, lenacapavir represents a significant advancement in HIV prevention, offering a convenient and highly effective option for those at risk. However, addressing systemic barriers to access and affordability will be crucial in ensuring that this innovative medication reaches those who need it most.